Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal transplantation to Eradicate Colonizing Emergent Superbugs (FECES)
2019-004402-10Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2020
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in bacterial colonization and Not applicable—colonization is not a disease comparing FMT frozen capsule arm with Placebo capsule arm (2 arms). Primary endpoint: Proportion of subjects decolonized of MDR-GNB at day 30. Started Feb 2020; status: active.
02
Drugs
fecal microbiome transplant
03
Conditions
bacterial colonizationNot applicable—colonization is not a disease
Beyond the preview
Go deeper on 2019-004402-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004402-10.